Eli Lilly and MacroGenics announced that they have suspended phase III trials of Protégé, a drug designed to address the autoimmune component in people with Type 1 diabetes, according to an article form InPharma.
The companies pulled the plug in the drug because it did not meet its primary goal. The companies said that there were no unanticipated safety issues, but that safety monitoring among trial participants is warranted.